Compare Cintas Corporation (CTAS) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Davita Inc — how do they compare? Cintas Corporation trades at $205.28 (market cap $82.15B), while Davita Inc trades at $179.02 (market cap $11.38B). The key difference: Cintas Corporation is far larger — about 7.2× Davita Inc's market cap, and Cintas Corporation pays a 1.01% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| CTAS | DVA | |
|---|---|---|
Market Cap | $82.15B | $11.38B |
Sector | Industrials | Health |
52-Week High | $225.10 | $240.96 |
52-Week Low | $163.55 | $103.87 |
Enterprise Value | $84.56B | $24.10B |
Dividend Yield | 1.01% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
